Literature DB >> 193440

Susceptibility of clinical isolates of cytomegalovirus to human interferon.

B Postic, J N Dowling.   

Abstract

Human cell culture-derived interferon was shown to inhibit human cytomegalovirus in vitro. A prototype strain, Davis, and six clinical isolates of cytomegalovirus were tested. All six isolates showed uniform susceptibility to interferon, exceeding that of the Davis strain by two- to fourfold. The latter virus was found to be 32 to 4 times less susceptible than the sensitive indicator, vesicular stomatitis virus. However, the laboratory finding of susceptibility to an antiviral material may not relate to its clinical effectiveness.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 193440      PMCID: PMC352045          DOI: 10.1128/AAC.11.4.656

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Interferon and cytomegalovirus in vivo and in vitro.

Authors:  L A Glasgow; J B Hanshaw; T C Merigan; J K Petralli
Journal:  Proc Soc Exp Biol Med       Date:  1967-07

2.  Experimental use of cytosine arabinoside in congenital cytomegalovirus infection.

Authors:  E N Kraybill; J L Sever; G B Avery; N Movassaghi
Journal:  J Pediatr       Date:  1972-03       Impact factor: 4.406

3.  Semi-micro, dye-binding assay for rabbit interferon.

Authors:  J A Armstrong
Journal:  Appl Microbiol       Date:  1971-04

Review 4.  The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I.

Authors:  T H Weller
Journal:  N Engl J Med       Date:  1971-07-22       Impact factor: 91.245

5.  Cytomegalovirus pneumonia after human marrow transplantation.

Authors:  J D Myers; H C Spencer; J C Watts; M B Gregg; J A Stewart; R H Troupin; E D Thomas
Journal:  Ann Intern Med       Date:  1975-02       Impact factor: 25.391

6.  The transplanted kidney as a source of cytomegalovirus infection.

Authors:  M Ho; S Suwansirikul; J N Dowling; L A Youngblood; J A Armstrong
Journal:  N Engl J Med       Date:  1975-11-27       Impact factor: 91.245

7.  Clinical efficacy of adenine arabinoside in therapy of cytomegalovirus infections in renal allograft recipients.

Authors:  M W Rytel; H M Kauffman
Journal:  J Infect Dis       Date:  1976-02       Impact factor: 5.226

8.  Effect of human exogenous leukocyte interferon in cytomegalovirus infections.

Authors:  G Emödi; R O'Reilly; A Müller; L K Everson; U Binswanger; M Just
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

9.  Effect of leukocyte interferon on urinary excretion of cytomegalovirus by infants.

Authors:  A M Arvin; A S Yeager; T C Merigan
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

10.  Cytomegalovirus infection in children undergoing open-heart surgery.

Authors:  J A Armstrong; G C Tarr; L A Youngblood; J N Dowling; A R Saslow; J P Lucas; M Ho
Journal:  Yale J Biol Med       Date:  1976-03
View more
  3 in total

1.  Treatment of a murine cytomegalovirus infection with exogenous interferon, polyinosinic-polycytidylic acid, and polyinosinic-polycytidylic acid-poly-L-lysine complex.

Authors:  E R Kern; G A Olsen; J C Overall; L A Glasgow
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

Review 2.  Molecular biology and immunology of cytomegalovirus.

Authors:  P D Griffiths; J E Grundy
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

3.  Prevention of Epstein-Barr virus-induced B-cell outgrowth by interferon alpha.

Authors:  J G Garner; M S Hirsch; R T Schooley
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.